EA033181B1 - Stable dosage form of etidronate-cytarabine conjugate, and use thereof - Google Patents

Stable dosage form of etidronate-cytarabine conjugate, and use thereof

Info

Publication number
EA033181B1
EA033181B1 EA201501157A EA201501157A EA033181B1 EA 033181 B1 EA033181 B1 EA 033181B1 EA 201501157 A EA201501157 A EA 201501157A EA 201501157 A EA201501157 A EA 201501157A EA 033181 B1 EA033181 B1 EA 033181B1
Authority
EA
Eurasian Patent Office
Prior art keywords
conjugate
etidronate
dosage form
parenteral administration
stable dosage
Prior art date
Application number
EA201501157A
Other languages
Russian (ru)
Other versions
EA201501157A1 (en
Inventor
Екатерина Алексеевна ИВАНОВА
Александр КАРПЕЙСКИЙ
Шон П. ЗИННЕН
Лиза Лынн Каралли
Рина Диана ФОНГ
Original Assignee
Общество С Ограниченной Ответственностью "Остерос Биомедика"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество С Ограниченной Ответственностью "Остерос Биомедика" filed Critical Общество С Ограниченной Ответственностью "Остерос Биомедика"
Priority to EA201501157A priority Critical patent/EA033181B1/en
Publication of EA201501157A1 publication Critical patent/EA201501157A1/en
Publication of EA033181B1 publication Critical patent/EA033181B1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to the field of medicine and pharmaceuticals and particularly to a stable lyophilizate for preparing a solution for parenteral administration for the treatment of primary bone cancer or bone lesion caused by a malignant neoplasm, and to a method for the preparation thereof. The stable lyophilizate comprises a trisodium salt of an etidronate-cytarabine conjugate and a stabilizer which is magnesium chloride in a molar ratio of 1:1 to 12:1. Such form ensures the hydrolytic and physical stability of the conjugate during long-term storage, and the stability of solutions of the conjugate for parenteral administration during clinical use.
EA201501157A 2015-12-09 2015-12-09 Stable dosage form of etidronate-cytarabine conjugate, and use thereof EA033181B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EA201501157A EA033181B1 (en) 2015-12-09 2015-12-09 Stable dosage form of etidronate-cytarabine conjugate, and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EA201501157A EA033181B1 (en) 2015-12-09 2015-12-09 Stable dosage form of etidronate-cytarabine conjugate, and use thereof

Publications (2)

Publication Number Publication Date
EA201501157A1 EA201501157A1 (en) 2017-06-30
EA033181B1 true EA033181B1 (en) 2019-09-30

Family

ID=59206013

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201501157A EA033181B1 (en) 2015-12-09 2015-12-09 Stable dosage form of etidronate-cytarabine conjugate, and use thereof

Country Status (1)

Country Link
EA (1) EA033181B1 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2068262C1 (en) * 1992-03-06 1996-10-27 Научно-исследовательский институт клинической и экспериментальной иммунологии Antileukosis medicinal preparation
CA2376258A1 (en) * 1999-06-02 2000-12-14 The Procter & Gamble Company Oral preparations of etidronate disodium
RU2002121643A (en) * 2000-01-20 2004-04-10 Ф.Хоффманн-Ля Рош Аг PHARMACEUTICAL PARENTERAL COMPOSITION CONTAINING BIPHOSPHONATE
WO2012008845A1 (en) * 2010-07-13 2012-01-19 Clavis Pharma Asa Parenteral formulations of elacytarabine derivatives

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677320B2 (en) * 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2068262C1 (en) * 1992-03-06 1996-10-27 Научно-исследовательский институт клинической и экспериментальной иммунологии Antileukosis medicinal preparation
CA2376258A1 (en) * 1999-06-02 2000-12-14 The Procter & Gamble Company Oral preparations of etidronate disodium
RU2002121643A (en) * 2000-01-20 2004-04-10 Ф.Хоффманн-Ля Рош Аг PHARMACEUTICAL PARENTERAL COMPOSITION CONTAINING BIPHOSPHONATE
WO2012008845A1 (en) * 2010-07-13 2012-01-19 Clavis Pharma Asa Parenteral formulations of elacytarabine derivatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SCHENKEIN D.P. et al. Accelerated bone formation causing profound hypocalcemia in acute leukemia. Ann Intern Med, 1986 Sep; 105(3): 375-8, реферат *
Описание. Osteros Biomedica, 2012-2013 [он-лайн] [найдено 2016-05-23]. Найдено из Интернет: <URL: http://www.osteros.ru/ru/content/%D0%BE%D0%BF%D0%B8%D1%81%D0%B0%D0%BD%D0%B8%D0%B5> *

Also Published As

Publication number Publication date
EA201501157A1 (en) 2017-06-30

Similar Documents

Publication Publication Date Title
CY1121698T1 (en) LIQUID INHALATION PREPARATION CONTAINING RPL554
SA515360469B1 (en) Heterocyclic compounds for inhibiting glutaminase and their methods of use
PH12016502355A1 (en) Pharmaceutical composition
EA201591890A1 (en) DERIVATIVES N-PHENYLCARBOXAMIDE AND THEIR USE AS A MEDICINE PREPARATION FOR THE TREATMENT OF HEPATITIS B
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington&#39;s disease
MX2014009757A (en) Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy.
CY1124970T1 (en) FUSIONED PYRAZOLE RING DERIVATIVES AND METHOD OF PREPARATION THEREOF AND THEIR APPLICATION IN THE TREATMENT OF CANCER, INFLAMMATION AND DISEASES OF THE IMMUNE SYSTEM
MA39765A (en) Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use
MY191380A (en) Stabilized fixed dose drug composition having mometasone and olopatadine
MX2019006207A (en) Polymorphic form of sepiapterin.
PH12016502352A1 (en) Pharmaceutical composition
PH12016502353A1 (en) Pharmaceutical composition
MX2018002223A (en) Novel insulin derivatives and the medical uses hereof.
MX2017003780A (en) Pharmaceutical composition for treating ulcerative colitis.
MX2020001875A (en) Polymorphic form of tg02.
EA035519B9 (en) 1,3,4-thiadiazole compounds and their use in treating cancer
TN2016000498A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine.
PH12020500374A1 (en) Treatment regimens
MX2017015664A (en) Intravenous administration of citrulline during surgery.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
EA033181B1 (en) Stable dosage form of etidronate-cytarabine conjugate, and use thereof
MX2019004822A (en) 3,4-bipyridyl pyrazole derivative, and preparation method therefor and medical application thereof.
ZA202200330B (en) Pharmaceutical composition of imatinib
EA202090452A1 (en) COMPOUNDS FOR TREATMENT OF DISEASE VON HIPPEL-LINDAU
PH12018502195A1 (en) Inhaled preparation of isoglycyrrhizic acid or salt thereof, and use in preparing drugs for treating respiratory system diseases

Legal Events

Date Code Title Description
PD4A Registration of transfer of a eurasian patent in accordance with the succession in title